Citations

Mayo Clinic

Showing 10 of 108602 citations.

HSR23-097: Health-Related Quality of Life in Patients With Metastatic Basal Cell Carcinoma Treated With Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial
Lewis, Karl D. , Quek, Ruben G.W. , Eroglu, Zeynep, Ivanescu, Cristina, Stratigos, Alexander , Sekulić, Aleksandar , Fury, Matthew G., Chen, Chieh-I, Inocencio, Timothy J. , LaFontaine, Patrick R. , Eroglu, Zeynep , Chang, Anne Lynn S. , Peris, Ketty

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: HSR23-097

10.6004/jnccn.2022.7161 Get It

BIO23-023: Supporting the Capture of Structured Data for Patients With Cancer Using Cancer-Specific Note Templates
Carroll, Cibele Barbosa , Stietz, Chelsea, Pier, Jeffrey B., Lavitschke, Michael D., Mulkerin, Daniel , Sesto, Mary E. , Tevaarwerk, Amye J., Emamekhoo, Hamid , Pier, Jeff

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: BIO23-023

10.6004/jnccn.2022.7233 Get It

CLO23-030: MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib (Futi) in Combination With Pembrolizumab (Pem) in Patients With FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma (aHCC)
Larson, Joseph J. , McCue, Shaylene , Fernández-Zapico, Martín E. , Revzin, Alexander , Fonkoua, Lionel Aurelien Kankeu , Flickinger, Lynn M. , Jatoi, Aminah , Tran, Nguyen H. , Ou, Fang‐Shu , Mahipal, Amit , Graham, Rondell P. , Cleary, Sean P. , Bekaii‐Saab, Tanios , Borad, Mitesh J. , McWilliams, Robert R. , Wee, Wen

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: CLO23-030

10.6004/jnccn.2022.7121 Get It

Treatment outcomes of extraskeletal Ewing sarcoma
Houdek, Matthew T. , Heidenreich, Mark J. , Ahmed, Safia K. , Petersen, Ivy A. , Rose, Peter S. , Allen-Rhoades, Wendy, Houdek, Matthew T , Allen‐Rhoades, Wendy , Siontis, Brittany L. , Robinson, Steven I.

Journal of Surgical Oncology | March 31, 2023 | Volume: 128 | Issue: 1 | Pages: 105-110

10.1002/jso.27250 | PMID 36999583 Get It

AbstractPurposeExtraskeletal Ewing sarcoma (EES), is a rare soft tissue sarcoma. Treatment for EES commonly involves chemotherapy and surgical resection (ST) or less commonly combined chemotherapy, surgery, and radiotherapy (ST + RT). The purpose of the current study was to evaluate our institutional experience treating EES.MethodsWe reviewed 36 (18 males:18 females) patients (mean age 30 years) with a nonretroperitoneal/visceral EES treated with either ST (n = 24, 67%) or ST + RT (n = 12, 33%). All patients were treated with chemotherapy, most commonly vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide (VDC/IE, n = 23, 66%) Radiotherapy was mostly delivered preoperatively (n = 9). The mean follow‐up was 8 years.ResultsThe 10‐year disease specific survival for patients was 78%, with no difference in the survival between patients in the ST versus the ST + RT groups (83% vs. 71%, p = 0.86). There was no difference in the 10‐year local recurrence (91% vs. 100%, p = 0.29) or metastatic free survival (87% vs. 75%, p = 0.45) between the ST and ST + RT groups.ConclusionThe results of the current study highlight the ability to achieve excellent local control with chemotherapy and surgery for EES. We recommend for multidisciplinary management of patients with EES, including chemotherapy and surgery, with use of radiotherapy if there is concern for a potentially close margin of resection.
Pharmacogenetic Interactions of Medications Administered for Weight Loss in Adults: A Systematic Review and Meta-Analysis
BouSaba, Joelle, Vosoughi, Kia , Camilleri, Michael , Dilmaghani, Saam , Camilleri, M , Prokop, Larry J.

Pharmacogenomics | March 31, 2023 | Volume: 24 | Issue: 5 | Pages: 283-295

10.2217/pgs-2022-0192 | PMID 36999540 Get It

A Broad Spectrum of Possibilities: Spectrum Scores as a Unifying Metric of Antibiotic Utilization
Ilges, Dan , Ilges, Dan , Tande, Aaron J. , Stevens, Ryan W.

Clinical Infectious Diseases | March 31, 2023 | Volume: 77 | Issue: 2 | Pages: 167-173

10.1093/cid/ciad189 | PMID 36999909 Get It

Abstract Days of therapy (DOT) currently serve as the standard antimicrobial utilization metric. However, by assigning the same weight to each agent rather than accounting for differences in spectrum of activity, DOT ignore key differences between agents that are fundamental to infectious diseases and critical to antimicrobial stewardship. Spectrum scoring assigns numeric values to individual antibiotic agents to quantify their spectrum of activity, allowing for the normalization of antibiotic utilization data. When used in conjunction with traditional metrics, spectrum scores may offer further clarity to antibiotic utilization; however, issues related to development, application, and standardization of spectrum scores remain. Despite these challenges, the potential applications of spectrum scores are vast. Here, we summarize existing data and explore the future of spectrum scoring, including application to both data analysis and routine patient care, use in inpatient and outpatient settings, integration within the electronic medical record, and opportunities for future research.
Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease
Makol, Ashima , Nagaraja, Vivek , Amadi, Chiemezie C. , Caoili, Elaine M. , Khanna, Dinesh , Khanna, Dinesh , Makol, Ashima , Nagaraja, Vivek , Pugashetti, Janelle Vu

Expert Review of Clinical Immunology | March 31, 2023 | Volume: 19 | Issue: 6 | Pages: 613-626

10.1080/1744666x.2023.2198212 | PMID 36999788 Get It

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
Javle, Milind , Mata, Helena Verdaguer, Braud, Filippo de , Trojan, Jörg , Ueno, Makoto, Lee, Choong‐kun , Cubillo, Antonio , Furuse, Junji , Azad, Nilofer S. , Vugmeyster, Yulia , Machl, Andreas, Bajars, Marcis, Oh, Do‐Youn , De Braud, Filippo , Yoo, Changhoon , Raoul, Jean‐Luc , Kim, Jin Won , Ueno, Makoto , Hijioka, Susumu , Furuse, Junji , Sato, Masashi , Bridgewater, John , Borad, Mitesh J.

Hepatology | March 31, 2023 | Volume: 78 | Issue: 3 | Pages: 758-770

10.1097/hep.0000000000000365 | PMID 36999533 Get It

Background and Aims: Biliary tract cancers are rare, heterogeneous cancers with poor prognoses. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 monoclonal antibody blocking programmed death ligand 1, was evaluated in patients with locally advanced/metastatic chemorefractory biliary tract cancers. Approach and Results: This multicenter, single-arm, open-label, phase 2 study (NCT03833661) enrolled adults with locally advanced or metastatic biliary tract cancer that was intolerant to or had failed first-line systemic platinum-based chemotherapy. Patients received 1200 mg bintrafusp alfa intravenously Q2W. The primary endpoint was confirmed objective response according to Response Evaluation Criteria in Solid Tumors 1.1 assessed by IRC. Secondary endpoints included duration of response, durable response rate, safety, progression-free survival, and overall survival. Between March 2019 and January 2020, 159 patients were enrolled. Median follow-up was 16.1 (range, 0.0–19.3) months; 17 patients (10.7%; 95% CI: 6.4%–16.6%) achieved an objective response. Median duration of response was 10.0 (range, 1.9–15.7) months; 10 patients (6.3%; 95% CI: 3.1%–11.3%) had a durable response (≥6 mo). Median progression-free survival was 1.8 months (95% CI: 1.7–1.8 mo); median overall survival was 7.6 months (95% CI: 5.8–9.7 mo). Overall survival rates were 57.9% (6 mo) and 38.8% (12 mo). Grade ≥3 adverse events occurred in 26.4% of patients, including one treatment-related death (hepatic failure). Frequent grade ≥3 adverse events included anemia (3.8%), pruritus (1.9%), and increased alanine aminotransferase (1.9%). Conclusions: Although this study did not meet its prespecified primary endpoint, bintrafusp alfa demonstrated clinical activity as second-line treatment in this hard-to-treat cancer, with durable responses and a manageable safety profile.
APOE ε4 influences within and between network functional connectivity in posterior cortical atrophy and logopenic progressive aphasia
Singh, Neha Atulkumar , Martin, Peter R. , Graff‐Radford, Jonathan , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Josephs, Keith A. , Whitwell, Jennifer L. , Singh, Neha Atulkumar , Machulda, Mary M. , Carrasquillo, Minerva M.

Alzheimer's & Dementia | March 31, 2023 | Volume: 19 | Issue: 9 | Pages: 3858-3866

10.1002/alz.13059 | PMID 36999481 Get It

AbstractIntroductionPresence of apolipoprotein E (APOE) ε4 has shown greater predisposition to medial temporal involvement in posterior cortical atrophy (PCA) and logopenic progressive aphasia (LPA). Little is known about its influence on memory network connectivity, a network comprised of medial temporal structures.MethodsFifty‐eight PCA and 82 LPA patients underwent structural and resting state functional magnetic resonance imaging (MRI). Bayesian hierarchical linear models assessed the influence of APOE ε4 on within and between‐network connectivity for five networks.ResultsAPOE ε4 carriers showed reduced memory and language within‐network connectivity in LPA and increased salience within‐network connectivity in PCA compared to non‐carriers. Between‐network analysis showed evidence of reduced DMN connectivity in APOE ε4 carriers, with reduced DMN‐to‐salience and DMN‐to‐language network connectivity in PCA, and reduced DMN‐to‐visual network connectivity in LPA.DiscussionThe APOE genotype influences brain connectivity, both within and between‐networks, in atypical Alzheimer's disease. However, there was evidence that the modulatory effects of APOE differ across phenotype.HIGHLIGHTS APOE genotype is associated with reductions in within‐network connectivity for the memory and language networks in LPA APOE genotype is associated with reductions in language‐to‐visual connectivity in LPA and PCA APOE genotype has no effect on the memory network in PCA
SARS-CoV-2 Infection, Inflammation, Immunonutrition, and Pathogenesis of COVID-19
Yu, Ligen , Ghani, Mohd Khanapi Abd , Aghemo, Alessio , Barh, Debmalya , Bassetti, Matteo , Catena, Fausto , Gallo, Gaetano , Gholamrezanezhad, Ali , Kamal, Mohammad Amjad , Lal, Amos , Sahu, Kamal Kant , Saxena, Shailendra K. , Elmore, Ugo , Rahimi, Farid , Robba, Chiara , Xia, Zhengyuan , Yu, Boxuan , Xia, Zhengyuan , Lal, Amos , Barh, Debmalya , Song, Yuanlin

Current Medicinal Chemistry | March 31, 2023 | Volume: 30 | Issue: 39 | Pages: 4390-4408

10.2174/0929867330666230330092725 | PMID 36998130 Get It

Abstract: The COVID-19 pandemic, caused by the coronavirus, SARS-CoV-2, has claimed millions of lives worldwide in the past two years. Fatalities among the elderly with underlying cardiovascular disease, lung disease, and diabetes have particularly been high. A biometrics analysis on author’s keywords was carried out, and searched for possible links between various coronavirus studies over the past 50 years, and integrated them. We found keywords like immune system, immunity, nutrition, malnutrition, micronutrients, exercise, inflammation, and hyperinflammation were highly related to each other. Based on these findings, we hypothesized that the human immune system is a multilevel super complex system, which employs multiple strategies to contain microorganism infections and restore homeostasis. It was also found that the behavior of the immune system is not able to be described by a single immunological theory. However, one main strategy is “self-destroy and rebuild”, which consists of a series of inflammatory responses: 1) active self-destruction of damaged/dysfunctional somatic cells; 2) removal of debris and cells; 3) rebuilding tissues. Thus, invading microorganisms’ clearance could be only a passive bystander response to this destroy–rebuild process. Microbial infections could be self-limiting and promoted as an indispensable essential nutrition for the vast number of genes existing in the microorganisms. The transient nutrition surge resulting from the degradation of the self-destroyed cell debris coupled with the existing nutrition state in the patient may play an important role in the pathogenesis of COVID-19. Finally, a possible coping strategies to mitigate COVID-19, including vaccination is also discussed.